Compare TATT & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TATT | ENTA |
|---|---|---|
| Founded | 1985 | 1995 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.2M | 407.5M |
| IPO Year | 1987 | 2013 |
| Metric | TATT | ENTA |
|---|---|---|
| Price | $43.16 | $16.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $47.25 | $20.40 |
| AVG Volume (30 Days) | 143.9K | ★ 375.0K |
| Earning Date | 11-12-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.30 | N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $172,525,000.00 | $65,324,000.00 |
| Revenue This Year | $20.32 | $0.99 |
| Revenue Next Year | $17.29 | $0.19 |
| P/E Ratio | $30.20 | ★ N/A |
| Revenue Growth | ★ 20.72 | N/A |
| 52 Week Low | $22.57 | $4.09 |
| 52 Week High | $45.83 | $15.86 |
| Indicator | TATT | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 63.35 | 72.47 |
| Support Level | $38.01 | $14.07 |
| Resistance Level | $40.52 | $15.28 |
| Average True Range (ATR) | 1.76 | 0.87 |
| MACD | 0.36 | 0.03 |
| Stochastic Oscillator | 99.30 | 88.28 |
TAT Technologies Ltd provides solutions and services to the commercial and military aerospace and ground defense industries, focused mainly on three product areas and services: Thermal Management, Power and Actuation, and Maintenance, Repair and Overhaul (MRO). Its product portfolio includes heat exchangers, cooling systems, and mechanical aircraft accessories and systems such as pumps, valves, and turbine power units. Its operating segments are MRO services for aviation components, which derive key revenue, Original equipment manufacturing (OEM) of heat transfer solutions and aviation accessories, MRO services for heat transfer components and OEM of heat transfer solutions, and Overhaul and coating of jet engine components. Geographically, it derives key revenue from the United States.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.